The episode unpacks Medvi’s explosive growth as a telehealth startup—projecting $1.8B in sales yet facing serious questions about its thin ~15% margins, heavy reliance on outsourced clinical infrastructure, and regulatory vulnerabilities, including an FDA warning letter for misbranding. It contrasts Medvi’s aggressive, compliance-avoidant marketing (e.g., fake credentials, misleading domains) with Juul’s more deliberate FDA engagement—and highlights how regulatory classification (tobacco vs. drug) dramatically shapes viability in nicotine-related businesses. The discussion pivots to broader themes: a solo developer’s $100M indie game success underscores enduring opportunity outside AI-driven models; China’s pork crisis reveals how overinvestment and shifting consumer habits can collapse commodity markets; and the U.S. military’s rapid fielding of the FLM-136 'Lucas' drone—reverse-engineered from Iranian tech and priced like a compact car—signals a strategic pivot toward affordable, mass-deployable unmanned systems over legacy high-cost platforms.